[EN] SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS [FR] IMIDAZOLE CARBOXAMIDES SUBSTITUÉS ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
[EN] SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS [FR] IMIDAZOLE CARBOXAMIDES SUBSTITUÉS ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
[EN] 6-SUBSTITUTED-3H-1,3-BENZOTHIAZOL-2-ONE COMPOUNDS AS TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS 3H-1,3-BENZOTHIAZOL-2-ONE 6-SUBSTITUÉS UTILISÉS EN TANT QU'ANTAGONISTES DU RÉCEPTEUR AMPA DÉPENDANT DE TARP-GAMMA
申请人:LILLY CO ELI
公开号:WO2015183673A1
公开(公告)日:2015-12-03
A TARP ϒ8 dependant AMPA receptor antagonist of the formula: wherein X is CH or N; A is; and R1 is as defined herein; its pharmaceutically acceptable salts, uses, and methods for its preparation are described.
6-SUBSTITUTED-3H-1,3-BENZOTHIAZOL-2-ONE COMPOUNDS AS TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONISTS
申请人:Eli Lilly and Company
公开号:US20150344468A1
公开(公告)日:2015-12-03
A TARP γ8 dependant AMPA receptor antagonist of the formula:
wherein X is CH or N;
A is
and
R
1
is as defined herein;
its pharmaceutically acceptable salts, uses, and methods for its preparation are described.
SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES
申请人:Masarykova univerzita
公开号:EP3556755A1
公开(公告)日:2019-10-23
The invention provides compounds represented by the structural formula (1):
wherein R1, R2, R3, R4, R5, R6 are as defined in the claims. The compounds are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.
SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
申请人:Bial - R&D Investments, S.A.
公开号:US20220411388A1
公开(公告)日:2022-12-29
The invention provides substituted imidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.